Unlike injectable GLP-1 treatments, orforglipron can be easily incorporated into daily life with minimal disruption.
Dubai: The UAE has fast-tracked approval of a new generation of weight-loss treatment, placing itself among the first countries in the world to offer an oral GLP-1 therapy.
The approval of Foundayo (orforglipron) marks a shift in obesity treatment—moving away from injections toward simpler, daily-use medication. However, for patients, it also brings immediate questions about access, affordability, and how it stacks up against alternatives still in development.
Shift from injections to routines
At the heart of this change is convenience. Unlike injectable GLP-1 therapies, orforglipron is designed to integrate seamlessly into daily life. It can be taken once a day, at any time, without restrictions on food or water intake.
That simplicity targets a key gap in treatment uptake. Despite the rising prominence of GLP-1 drugs, fewer than one in ten people who could benefit are currently using them. Barriers range from cost and access to stigma, as well as the perception that obesity is not a condition requiring medical treatment.
A once-daily pill helps address several of these challenges:
- No need for injections or clinical handling
- No timing constraints around meals or hydration
- Easier integration into work, travel, and daily schedules
Clinical data also supports its role as a long-term management tool rather than a short-term fix. In trials, participants taking the highest dose of orforglipron lost an average of 27.3 pounds, or 12.4 per cent of their body weight. The treatment was also associated with improvements in cardiovascular risk markers, including cholesterol levels, waist circumference, and blood pressure.
Approval for one, review ongoing for another
The UAE’s approval of Foundayo comes as the oral version of Wegovy (semaglutide) remains under regulatory review, following its approval in the United States in late 2025.
The difference reflects the distinct regulatory pathways for each treatment.
Wegovy’s tablet is treated as a new formulation and is therefore subject to a separate evaluation process, despite the injectable version already being approved. Its global rollout is also more closely aligned with European regulatory timelines, which can influence the sequence of approvals in other markets, including the UAE.
In parallel, UAE authorities have prioritised the early registration of orforglipron as part of a broader push to accelerate access to innovative therapies.
UAE among first to approve treatment
The country is among the first globally to approve the drug, underscoring its focus on expanding patient options and supporting a shift toward more convenient, non-injectable care.
As a result, patients in the UAE currently have access to one oral GLP-1 therapy, while additional options remain under review. Further approvals are expected to broaden the range of available treatments over time.
Emerging data continues to shape how these therapies compare. Findings from the ORION study suggest that oral semaglutide may be linked to greater weight loss and lower discontinuation rates due to side effects compared with orforglipron, although these insights are based on indirect comparisons rather than head-to-head trials. Patient preference research has also pointed to strong interest in semaglutide-like treatment profiles.
For now, availability largely reflects regulatory timelines, with treatment options expected to expand as further approvals are completed.
Cost, coverage, access?
Pricing is likely to be the next key factor influencing adoption.
In the US, orforglipron is expected to cost as little as $25 per month for patients with commercial insurance, rising to around $149 per month for those paying out of pocket. While UAE pricing has yet to be announced, these figures offer a rough benchmark for what patients might expect.
Access will likely depend on several factors:
- Whether insurers classify obesity treatment as essential care
- The extent of reimbursement for long-term use
- Out-of-pocket affordability for patients without coverage
The long-term nature of treatment adds to the financial considerations. GLP-1 therapies are designed for sustained use, meaning costs accumulate over time rather than being limited to a short course.
What comes next?
The UAE’s push to accelerate access to obesity treatments reflects the scale of the challenge. Obesity is linked to more than 200 diseases and health complications, including type 2 diabetes, hypertension, and several forms of cancer.
Expanding treatment options is increasingly viewed as part of a broader effort to reduce long-term healthcare burdens and improve population health outcomes.
Further developments are expected in the coming months, including the commercial rollout of orforglipron and potential progress on the approval of competing therapies like oral Wegovy.
As more options reach the market, focus is likely to shift from mere availability to differentiation—how treatments compare in effectiveness, tolerability, and cost.
For patients, the change is already tangible. Weight-loss treatment is moving out of specialised clinical settings and into everyday routines, shaped not only by clinical outcomes but also by how seamlessly therapies fit into daily life—and whether people can afford to continue them long term.
